The appraisal committee has prepared final draft guidance (FDG) on Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma and submitted it to NICE.
The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FDG may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, Friday 9 August 2024
This page was last updated: